Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

The Role of PCSK9 Inhibition and Small Interference RNA (siRNA) in The Management of Dyslipidaemia and ASCVD

The Indonesian Biomedical Journal · Vol. 18 No. 2 (2026) · hlm. 107–117

DOI
10.18585/inabj.v18i2.4041
ISSN
2085-3297, 2355-9179
Terbit
2026-04-29
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

Compelling evidence linking low-density lipoprotein cholesterol (LDL-C) reduction to decreased mortality has positioned LDL-C lowering as a central strategy in the prevention of atherosclerotic cardiovascular disease (ASCVD). Nonetheless, despite widespread statin use, an estimated 10–20% of individuals at high or very high cardiovascular risk fail to attain guideline-recommended LDL-C targets. This persistent treatment gap underscores the need for more potent and durable lipid-lowering strategies, particularly among patients with familial hypercholesterolemia (FH) and those with established ASCVD whose LDL-C levels remain inadequately controlled despite optimized combination therapy, including statins, ezetimibe, and proprotein convertase subtilisin–kexin type 9 (PCSK9) monoclonal antibodies. Inclisiran, a first-in-class small interfering RNA agent, addresses this unmet need by selectively inhibiting hepatic synthesis of PCSK9, thereby enhancing low-density lipoprotein receptor (LDLR) recycling and accelerating LDL-C clearance. Nevertheless, thus far, no cardiovascular outcome trial (CVOT) has been available. With a convenient twice-yearly dosing regimen, inclisiran consistently achieves LDL-C reductions exceeding 50% and demonstrates a favourable tolerability profile, offering an effective and patient-friendly advancement in dyslipidaemia management.KEYWORDS: dyslipidaemia, ASCVD, PCSK9 inhibition, siRNA, inclisiran

Kata kunci

Jaringan kolaborasi para penulis

23 penulis · 65 tautan kepenulisan bersama · 42 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • University of Indonesia
  • Udayana University
  • Universitas Airlangga
  • Universitas Trisakti
  • University of Brawijaya
  • Universitas Hang Tuah
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Andi WijayaHasanuddin University4
Mansyur ArifHasanuddin University3
Erizal SugionoHasanuddin University2
Marsetio DonosepoetroUniversitas Airlangga2
Mona YolandaHasanuddin University2
Susana GunawanHasanuddin University1
Ferry SandraUniversitas Trisakti1
Irawan YusufHasanuddin University1
Ilham Jaya PatellongiHasanuddin University1
Syakib BakriHasanuddin University1
Lies GantiniHasanuddin University1
Diah KumalasariHasanuddin University1
Dedeh YuniartyAfiliasi tidak diketahui1
Bambang Budi SiswantoUniversity of Indonesia1
Lutfah Rif’atiNational Research and Innovation Agency1
Syntia NusantiUniversity of Indonesia1
Wienta DiarsvitriUniversitas Hang Tuah1
Seskoati PrayitnaningsihUniversity of Brawijaya1
Virna Dwi OktarianaUniversity of Indonesia1
Sri Wardani WardaniRumah Sakit Umum Pusat Sanglah Denpasar1
Ketut SurayanaUdayana University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">The Role of PCSK9 Inhibition and Small Interference RNA (siRNA) in The Management of Dyslipidaemia and ASCVD</dc:title><dc:creator>Anwar Santoso</dc:creator><dc:creator>Bambang Dwiputra</dc:creator><dc:subject>PCSK9 inhibition</dc:subject><dc:subject>inclisiran</dc:subject><dc:subject>siRNA</dc:subject><dc:subject>dyslipidemia</dc:subject><dc:subject>atherosclerotic cardiovascular disease</dc:subject><dc:subject>LDL cholesterol lowering</dc:subject><dc:subject>familial hypercholesterolemia</dc:subject><dc:subject>LDL receptor recycling</dc:subject><dc:subject>PCSK9 monoclonal antibodies</dc:subject><dc:subject>ezetimibe</dc:subject><dc:subject>statins</dc:subject><dc:subject>cardiovascular outcome trials</dc:subject><dc:description xml:lang="en">Compelling evidence linking low-density lipoprotein cholesterol (LDL-C) reduction to decreased mortality has positioned LDL-C lowering as a central strategy in the prevention of atherosclerotic cardiovascular disease (ASCVD). Nonetheless, despite widespread statin use, an estimated 10–20% of individuals at high or very high cardiovascular risk fail to attain guideline-recommended LDL-C targets. This persistent treatment gap underscores the need for more potent and durable lipid-lowering strategies, particularly among patients with familial hypercholesterolemia (FH) and those with established ASCVD whose LDL-C levels remain inadequately controlled despite optimized combination therapy, including statins, ezetimibe, and proprotein convertase subtilisin–kexin type 9 (PCSK9) monoclonal antibodies. Inclisiran, a first-in-class small interfering RNA agent, addresses this unmet need by selectively inhibiting hepatic synthesis of PCSK9, thereby enhancing low-density lipoprotein receptor (LDLR) recycling and accelerating LDL-C clearance. Nevertheless, thus far, no cardiovascular outcome trial (CVOT) has been available. With a convenient twice-yearly dosing regimen, inclisiran consistently achieves LDL-C reductions exceeding 50% and demonstrates a favourable tolerability profile, offering an effective and patient-friendly advancement in dyslipidaemia management.KEYWORDS: dyslipidaemia, ASCVD, PCSK9 inhibition, siRNA, inclisiran</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2026-04-29</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v18i2.4041</dc:identifier><dc:identifier>10.18585/inabj.v18i2.4041</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 18 No 2 (2026); 107-117</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/4041/830</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>